Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
HZNP was delisted on the 5th of October, 2023.
67 hedge funds and large institutions have $119M invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2013 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 30 increasing their positions, 12 reducing their positions, and 8 closing their positions.
2,110% more call options, than puts
Call options by funds: $4.2M | Put options by funds: $190K
150% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 12
113% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 8
53% more capital invested
Capital invested by funds: $77.9M → $119M (+$41M)
14% more funds holding
Funds holding: 59 → 67 (+8)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$4.96M |
| 2 |
BPCM
Beach Point Capital Management
Santa Monica,
California
|
+$3.59M |
| 3 |
JGC
J. Goldman & Co
New York
|
+$1.48M |
| 4 |
KCM
Kingdon Capital Management
New York
|
+$1.12M |
| 5 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$786K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.01M |
| 2 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$923K |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$295K |
| 4 |
SIP
Stoneridge Investment Partners
Radnor,
Pennsylvania
|
-$86K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$79.9K |
HZNP Hedge Fund Activity: Q3 2013 in Review
67 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q3 2013, worth a combined $119M — up 53% from $77.9M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new HZNP positions and 8 closed out — a net gain of 9 holders — while 30 added to existing stakes and 12 trimmed.
The largest buyer was Broadfin Capital, opening a new position worth an estimated $4.96M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $1.01M sold.
- 67 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q3 2013, up from 59 in Q2 2013.
- Funds reported $119M of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q3 2013, up 53% quarter-over-quarter.
- 17 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q3 2013 and 8 closed out, a net change of +9 holders.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q3 2013 was Broadfin Capital, an estimated $4.96M added.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q3 2013 was Alyeska Investment Group, an estimated $1.01M sold.
Based on aggregated 13F filings for Q3 2013.